General Question for the Week of May 5, 2025
Under what circumstances can code 96376 be reported in conjunction with 96374 or 96375 for IV push administrations?
Under what circumstances can code 96376 be reported in conjunction with 96374 or 96375 for IV push administrations?
What steps is CMS taking to improve access to high-cost specialty drugs, particularly for underserved populations served by Indian Health Service and tribal hospitals?
CMS just finalized a policy to pay for non-opioid pain treatments. Why does this matter, especially for heart patients?
Can we bill 36415 for blood returned (or collected) after insertion of IV access and bill as a specimen collection?
What is the difference between oral hydration and intravenous hydration therapy?
What recent change has CMS made regarding Intensive Outpatient Programs (IOPs), and how does it impact treatment options for patients with opioid use disorder (OUD) and cardiovascular conditions?
What does the CMS market basket adjustment mean for OPPS payments in 2025?
Why can’t we code 95180 (rapid desensitization) and chemotherapy drug administration codes together when we perform carboplatin desensitization?
Why are CMS market baskets important?
How would we bill the concurrent IV administration of one chemotherapy drug and one non-chemotherapy when the drugs are given in separate bags at the same site?
What is the significance of the 2025 OPPS updates for cardiology, and how does the CMS market basket index help track healthcare inflation?
When do we report the JW modifier?
Subscribe to receive our News, Insights, and Compliance Question of the Week articles delivered right to your inbox.
Subscribe to receive our News, Insights, and Compliance Question of the Week delivered right to your inbox.
Address: 5874 Blackshire Path, #13, Inver Grove Heights, MN 55076
Phone: (800) 252-1578
Email: support@medlearnmedia.com
Hours: 9am – 5pm CT
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24